Literature DB >> 12682916

Estrogen receptor-beta modulates synthesis of bone matrix proteins in human osteoblast-like MG63 cells.

Lihuan Cao1, Rongfa Bu, Jennifer I Oakley, Sara E Kalla, Harry C Blair.   

Abstract

Estrogens have complex effects on the skeleton, including regulation of modeling and maintenance of bone mass, which vary with cell type and developmental stage. Osteoblasts are key regulators of skeletal matrix synthesis and degradation. However, whether osteocytes, osteoblasts or earlier progenitors mediate estrogen effects, and the importance of estrogen receptors (ERs) alpha and beta, remain unclear. To address estrogen response in human cells closely related to secretory osteoblasts, we studied MG63 cells with ERalpha or ERbeta reduced to low levels by stable transfection of antisense plasmids. Collagen and alkaline phosphatase expression increased with estrogen in wild-type and ERalpha-suppressed cells, but not in ERbeta-suppressed cells. Matrix secretion occurs as osteoblasts cease dividing, and, in keeping with this, cell proliferation was reduced by estrogen except in ERbeta-antisense cells. No effects of estrogen on wild type or ER-suppressed cells were seen in expression of BMP 2, the BMP antagonist noggin, or Indian hedgehog, products that regulate differentiation of osteoblasts. In contrast to expectations that estrogen would modulate bone degradation, RANKL, CSF-1, and osteoprotegerin did not respond measurably to estrogen, regardless of ER status. In keeping with this result, estrogen response was not observed in assays of osteoclast development from CD14 cells supported by wild-type or ER-silenced MG63 cells. Since estrogens are major regulators of bone degradation in vivo, estrogen effects on osteoclasts may depend on interaction with stimuli present in bone but absent in the model studied. cDNA hybridization showed that additional estrogen-binding proteins including ERRalpha and BCAR3 were expressed by MG63, but estrogen effects in ERbeta-silenced cells were small, so these proteins are either minor regulators in MG63 cells, or act in concert with stimuli in addition to estrogen. We conclude that, in the MG63 cell line, estrogen increases synthesis of matrix proteins via ERbeta, and that, in the absence of additional stimuli, these cells are not major mediators of estrogen effects on osteoclast differentiation. Further, ERalpha is probably much more important in earlier stages of skeletal development, such as growth plate response, than in osteoblasts. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682916     DOI: 10.1002/jcb.10486

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  11 in total

1.  Pyk2 deficiency potentiates osteoblast differentiation and mineralizing activity in response to estrogen or raloxifene.

Authors:  Sumana Posritong; Jung Min Hong; Pierre P Eleniste; Patrick W McIntyre; Jennifer L Wu; Evan R Himes; Vruti Patel; Melissa A Kacena; Angela Bruzzaniti
Journal:  Mol Cell Endocrinol       Date:  2018-02-08       Impact factor: 4.102

2.  The response to sex steroid hormones and vitamin D of cultured osteoblasts derived from ovariectomized mice with and without 17beta-estradiol pretreatment.

Authors:  Natan Patlas; Yehuda Zadik; Pirhya Yaffe; Michael Patlas; Zvi Schwartz; Asher Ornoy
Journal:  Odontology       Date:  2005-09       Impact factor: 2.634

3.  Glycitein decreases the generation of murine osteoclasts and increases apoptosis.

Authors:  Maria Winzer; Martina Rauner; Peter Pietschmann
Journal:  Wien Med Wochenschr       Date:  2010-08-16

4.  A diarylheptanoid phytoestrogen from Curcuma comosa, 1,7-diphenyl-4,6-heptadien-3-ol, accelerates human osteoblast proliferation and differentiation.

Authors:  Duangrat Tantikanlayaporn; Lisa J Robinson; Apichart Suksamrarn; Pawinee Piyachaturawat; Harry C Blair
Journal:  Phytomedicine       Date:  2013-04-01       Impact factor: 5.340

5.  Danshen (Salvia miltiorrhiza) protects ovariectomized rats fed with high-saturated fat-sucrose diet from bone loss.

Authors:  X L Dong; W X Yu; C M Li; S He; L P Zhou; C W Poon; M S Wong
Journal:  Osteoporos Int       Date:  2017-10-23       Impact factor: 4.507

6.  Estrogen receptor α mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain, but their acute down-regulation of the Wnt antagonist Sost is mediated by estrogen receptor β.

Authors:  Gabriel L Galea; Lee B Meakin; Toshihiro Sugiyama; Noureddine Zebda; Andrew Sunters; Hanna Taipaleenmaki; Gary S Stein; Andre J van Wijnen; Lance E Lanyon; Joanna S Price
Journal:  J Biol Chem       Date:  2013-01-29       Impact factor: 5.157

Review 7.  Osteoclastic differentiation and function regulated by old and new pathways.

Authors:  Harry C Blair; Mone Zaidi
Journal:  Rev Endocr Metab Disord       Date:  2006-06       Impact factor: 9.306

8.  Megakaryocytes promote osteoclastogenesis in aging.

Authors:  Deepa Kanagasabapathy; Rachel J Blosser; Kevin A Maupin; Jung Min Hong; Marta Alvarez; Joydeep Ghosh; Safa F Mohamad; Alexandra Aguilar-Perez; Edward F Srour; Melissa A Kacena; Angela Bruzzaniti
Journal:  Aging (Albany NY)       Date:  2020-07-07       Impact factor: 5.682

9.  A chinese herbal decoction, danggui buxue tang, stimulates proliferation, differentiation and gene expression of cultured osteosarcoma cells: genomic approach to reveal specific gene activation.

Authors:  Roy C Y Choi; Qiu T Gao; Anna W H Cheung; Judy T T Zhu; Faye T C Lau; Jun Li; Winnie Z M Li; Glanice K Y Chu; Ran Duan; Jerry K H Cheung; An W Ding; Kui J Zhao; Tina T X Dong; Karl W K Tsim
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-18       Impact factor: 2.629

10.  Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.

Authors:  Xuelei Yin; Shuaishuai Feng; Yingying Chi; Jinhu Liu; Kaoxiang Sun; Chuanyou Guo; Zimei Wu
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.